Strategic Acquisition Following the May 2026 acquisition by RealCold, SCL Cold Chain’s expanded pharmaceutical logistics capabilities and CEIV Certification can be leveraged to cross-sell advanced temperature-controlled solutions to existing RealCold clients and complement partner networks.

Pharma Expansion Fit SCL’s established pharma and medical devices handling, combined with CEIV expertise, positions it as a near-term integration target for customers seeking compliant, end-to-end cold chain services across healthcare and life sciences sectors.

Diversified Sectors SCL supports food, pharma, flowers, and fresh goods, enabling a broad cross-sell play across multiple verticals that require temperature-controlled transport, potentially expanding wallet share with existing customers and new prospects in each segment.

Geographic Footprint Headquarters near DFW with satellite offices in Houston and Greensboro offers a regional coverage advantage and a chance to upsell to shippers requiring multi-region cold chain capabilities in the central and southern United States.

Financial Footprint With reported revenue in the $10M–$25M range and a scalable, mid-market profile, there is opportunity to pursue tiered service expansions, premium pharma logistics offerings, and contract modernization deals with mid-market and larger shippers seeking reliability and regulatory compliance.